Matthew J. Kuhn1, Howard A. Rowley2,
Cesare Colosimo3, Michael V. knopp4, Kenneth R.
Maravilla5, Zoran Rumboldt6
1Radiology, University of Illinois at
Peoria, Peoria, IL, United States; 2Radiology, University of
Wisconsin, Madison, WI, United States; 3Radiology, University of
the Sacred Heart, Rome, Italy; 4Radiology, Ohio State University,
Columbus, OH, United States; 5Radiology and Surgery, University of
Washington, Seattle, WA, United States; 6Radiology, Medical
University of South Carolina, Charleston, SC, United States
Safety
results from 5 prospective, randomized, intraindividual crossover comparison
studies of gadobenate dimeglumine with other gadolinium agents for magnetic
resonance imaging (MRI) of the central nervous system (CNS) are reviewed. The
overall rate of adverse events in these studies was 6.0%. The type and rate
of adverse events was similar after gadobenate dimeglumine and the comparator
agents with no significant differences noted between agents in any study.